Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Chardan Capital
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. Chardan Capital’s price target suggests a potential upside of 208.37% from the company’s current price. Several other […]
More Stories
Global X Data Center & Digital Infrastructure ETF (NASDAQ:DTCR) Sees Significant Decline in Short Interest
Global X Data Center & Digital Infrastructure ETF (NASDAQ:DTCR – Get Free Report) saw a large drop in short interest...
Reviewing Peninsula Energy (OTCMKTS:PENMF) and IperionX (NASDAQ:IPX)
IperionX (NASDAQ:IPX – Get Free Report) and Peninsula Energy (OTCMKTS:PENMF – Get Free Report) are both industrial products companies, but...
DWS Municipal Income Trust (NYSE:KTF) Short Interest Down 29.3% in October
DWS Municipal Income Trust (NYSE:KTF – Get Free Report) was the target of a significant decline in short interest in...
Marin Software Incorporated (NASDAQ:MRIN) Short Interest Down 28.9% in October
Marin Software Incorporated (NASDAQ:MRIN – Get Free Report) was the recipient of a significant drop in short interest during the...
Galantas Gold (CVE:GAL) Hits New 12-Month Low – What’s Next?
Galantas Gold Co. (CVE:GAL – Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded...
Trio Petroleum Corp. (NYSEAMERICAN:TPET) Sees Significant Decline in Short Interest
Trio Petroleum Corp. (NYSEAMERICAN:TPET – Get Free Report) was the target of a significant decline in short interest in the...